New Risk • May 13
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (kr79.4m market cap, or US$8.67m). Annuncio • Mar 21
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 388,240
Price\Range: NOK 5
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 348,240
Price\Range: NOK 5
Transaction Features: Rights Offering Annuncio • Feb 13
Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 800,000
Price\Range: NOK 5
Transaction Features: Rights Offering New Risk • Dec 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr77.9m market cap, or US$7.69m). New Risk • Dec 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr79.0m market cap, or US$7.81m). Reported Earnings • Dec 01
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance. New Risk • Dec 01
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (kr53.3m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity). Annuncio • Nov 22
Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026 Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (kr85.9m market cap, or US$8.54m). Annuncio • May 22
Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC). Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025.
In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash. Annuncio • May 21
Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC). Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025.
In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash. Annuncio • Apr 09
Aqua Bio Technology Asa Announces Board Changes Aqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer. Annuncio • Apr 04
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,111,975
Price\Range: NOK 0.5
Transaction Features: Rights Offering Annuncio • Mar 13
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 48,432,000
Price\Range: NOK 0.5
Transaction Features: Subsequent Direct Listing New Risk • Mar 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr80.1m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (kr80.1m market cap, or US$7.43m). Annuncio • Feb 12
Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025 Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024. Annuncio • Jan 21
Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of Directors Aqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment. New Risk • Dec 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr234.0m market cap, or US$20.6m). New Risk • Nov 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (kr217.7m market cap, or US$19.6m). New Risk • Nov 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (kr191.1m market cap, or US$17.3m). Annuncio • Oct 22
Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024 Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021. Annuncio • Aug 29
Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS. Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors.
Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group"). New Risk • Aug 25
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr245.0m market cap, or US$23.4m). New Risk • Jun 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr227.8m market cap, or US$21.5m). New Risk • Mar 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr246.8m market cap, or US$23.7m). Annuncio • Feb 01
Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,000,000
Price\Range: NOK 5
Transaction Features: Rights Offering Annuncio • Dec 21
Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million. Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million. New Risk • Sep 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr196.3m market cap, or US$18.3m). Annuncio • Sep 13
Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic Formulations Aqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT. New Risk • Aug 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$668k). Market cap is less than US$10m (kr78.7m market cap, or US$7.34m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Annuncio • Jul 26
Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in funding On July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company. New Risk • Jul 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$709k). Market cap is less than US$10m (kr99.2m market cap, or US$9.82m). Annuncio • Jul 25
Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in funding Aqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023. Annuncio • Jul 24
Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million. Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3. Annuncio • Jan 21
Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023 Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Recent Insider Transactions • Mar 10
Chief Executive Officer recently bought kr55k worth of stock On the 9th of March, Håvard Lindstrøm bought around 5k shares on-market at roughly kr10.97 per share. This was the largest purchase by an insider in the last 3 months. This was Håvard's only on-market trade for the last 12 months. Recent Insider Transactions • Jun 24
Insider recently sold kr1.9m worth of stock On the 23rd of June, Espen Dahl sold around 100k shares on-market at roughly kr19.49 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr55m more than they sold in the last 12 months. Recent Insider Transactions • Apr 21
Director recently bought kr57m worth of stock On the 20th of April, Roger Hofseth bought around 4m shares on-market at roughly kr12.72 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr58m more in shares than they have sold in the last 12 months. Annuncio • Mar 05
Aqua Bio Technology ASA Announces Strategic Partnership with DCP Dermoscience Aqua Bio Technology (ABT) has entered into a strategic partnership with the Canadian company DCP Dermoscience (DCP). The DCP agreement gave ABT exclusive rights to two new skin care series for development of its own brands and "private label" for ABT's customers. The first two skin care series following from the DCP agreement will be named "Seidr" and "Seidr Clinique". The name "Seidr" comes from Norse mythology and refers to supernatural abilities and powers practiced by strong women. The new brand "Seidr" is developed in close cooperation with the media bureau Glitch Studios. Both "Seidr" and "Seidr Clinique", like ABT's existing products, will contain high levels of active ingredients. Annuncio • Feb 26
Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Moana Active Skincare Limited for New Zealand and Australia Aqua Bio Technology ASA has signed an exclusive distribution agreement with Moana Active Skincare Limited for New Zealand and Australia. As informed in the stock exchange announcement on 10 September 2020, ABT retains its local presence and knowledge through the conclusion of an agreement with Moana Skincare New Zealand Limited. The duration of the agreement is three years. Annuncio • Feb 13
Aqua Bio Technology ASA Signs an Distribution Agreement with Galaxa Pharma Aps Aqua Bio Technology ASA has signed an distribution agreement with Galaxa Pharma Aps (Galaxa). The agreement grants Galaxa distribution rights for Denmark for the certified organic skincare line Moana Skincare. ABT has previously announced its acquisition of all rights to Moana Skincare. Galaxa has since 2014 been commercially active in Denmark as a representative of various foreign producers, with sales through drugstores (Matas), pharmacies and its own web shop. Annuncio • Feb 05
Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Cosmed Beauty AS Aqua Bio Technology ASA (ABT) has signed an exclusive distribution agreement with Cosmed Beauty AS (Cosmed). The agreement grants Cosmed exclusive distribution rights for Norway for the certified organic skincare line Moana Skincare. ABT has previously announced its acquisition of all rights to Moana Skincare. The initial term of the agreement is three years. Cosmed has shown continuous growth in the market and has established a distribution model that covers about approx. 900 stores. Is New 90 Day High Low • Jan 21
New 90-day high: kr9.20 The company is up 79% from its price of kr5.15 on 23 October 2020. The Norwegian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period. Recent Insider Transactions • Jan 20
Director recently bought kr141k worth of stock On the 18th of January, Roger Hofseth bought around 25k shares on-market at roughly kr5.64 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.2m more in shares than they have sold in the last 12 months. Annuncio • Dec 16
Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies of 6 Products from the Product Series Balance & Vitality Aqua Bio Technology ASA announced that reference is made to the stock exchange announcement of 26 November 2020 regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. The company has received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 18 products are expected in January 2021, while the last 3 products are expected to be approved during first quarter 2021. Balance & Vitality will be a complete skincare series with products in all categories. The tests were performed at Eurofins. ABT expects the Balance & Vitality product series to be ready for distribution and sale in the first half of 2021. Annuncio • Dec 13
Aqua Bio Technology Asa: Hydrafacial Has Entered into Partnership with Restorsea - Conversion Lab Launches Veritas Md Platform Aqua Bio Technology ASA has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. The positive trend from Restorsea's commercialization of ABT's proprietary
technology increases the likelihood that ABT will receive additional renewal payment and increased revenue from the sale of ingredients and royalties from Restorsea and its licensees. Annuncio • Dec 12
Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP. Aqua Bio Technology ASA (OB:ABT) has signed a letter of intent to acquire distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP on August 2, 2019. Aqua Bio Technology ASA (OB:ABT) agreed to acquire the distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP for NOK 32.5 million on September 10, 2020. Aqua Bio Technology ASA will pay consideration of NOK 26.7 million with three initial payment of NZD 0.5 million (NOK 3 million), second initial payment of NZD 0.25 million (NOK 1.5 million) and third initial payment of NZD 0.21 million (NOK 1.3 million) of NOK 5.8 million. The positive financial consequences of the acquisition will be significant in the event of successful revenue growth.
Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP on December 10, 2020. Annuncio • Dec 11
Aqua Bio Technology ASA Expects to Enter into Three-Year Agreement for the Distribution of Moana Products in New Zealand and Australia Aqua Bio Technology ASA expected to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled nature. These have been used in traditional medicine by the country's indigenous people, the Maori, for centuries. The cornerstone of Moana Skincare's skin care products is a certified organic red seaweed found in the waters around New Zealand. Annuncio • Nov 28
Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies by Nordic Beauty Aqua Bio Technology ASA announced that it received confirmation from Eurofins that Nordic Beauty has passed all the safety studies that the EU requires to be carried out before commercialization. The tests were performed at Eurofins. ABT expects the Nordic Beauty product series to be ready for distribution and sale in the first half of 2021. Annuncio • Sep 12
Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million. Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 505,200
Price\Range: NOK 5
Transaction Features: Rights Offering